A major hallmark of Alzheimer's disease (AD) is the accumulation of neurotoxic p-amyloid (A(3) peptide in the? brain. Inappropriate oligomerization of Ap peptides into soluble high molecular weight (HMW) species and? the eventual deposition of A(3 peptides into extracellular A(3 plaques in the brain are major events involved in? AD neuropathology and associated dementia. Accumulating evidence indicates a central role for soluble A|3? oligomers (with molecular weight higher than tetramers but lower than decamers) in preclinical AD cognitive? deterioration as well as in AD dementia. The overall goal of the proposed studies in Project 3 is to identify? bioactive grape seed extract (GSE)- polyphenolic compounds that can prevent AD-type amyloid? neuropathology and cognitive deterioration in the Tg2576 mouse model of AD. The proposed studies are? supported by preliminary evidence showing that a commercially available GSE (herein defined as NS-MA2? GSE) containing a variety of polyphenolic compounds, prevents the oligomerization of Ap peptides into? soluble-extracellular HMW species and eventually AD - type Ap neuropathology, coincidental with the? attenuation of spatial reference memory impairment in Tg2576 mice. Based on this consideration, the? proposed studies are specifically designed to further identify and document how NS-MA2 GSE polyphenolic? compounds are absorbed, metabolized and ultimately prevent AD-type cognitive deterioration in Tg2576? mice. The proposed studies will be the first to systematically identify GSE polyphenolic compounds in vivo? using a combination of LC-tandem mass spectrorhetry and NMR techniques. Furthermore, this approach will? make use of 14C labeled grape fractions and Accelerator Mass Spectrometry to accurately determine the? pharmacokinetics of NS-MA2 GSE polyphenolic compounds in plasma and in the brain. Data from the? proposed studies will provide impetus for immediate application to prevention of cognitive deterioration in? AD, and potentially also in mild cognitive impairment (MCI), whose subjects are at high risk of developing AD? dementia.?
Showing the most recent 10 out of 37 publications
